Roowin

Executive Summary

Roowin is a privately-owned French Contract Research Organisation (CRO) established in 2017, headquartered in Riom (Clermont-Ferrand). The company specializes in high-value fine chemistry and cGMP production for small molecule drug development, offering integrated services from early drug discovery and process chemistry through to clinical-phase manufacturing. It supports clients up to Phase II API licensing and small-scale commercial production, positioning itself as a bridge between novel chemical entity discovery and clinical success. With a focus on high-quality synthesis and regulatory compliance, Roowin serves biopharma companies seeking reliable CRO partners in Europe. Despite being a private entity with no disclosed funding or valuation, its niche expertise in fine chemistry and cGMP manufacturing positions it well in the competitive CRO landscape. The company appears to be operationally focused, with a lean profile and no public fundraising history, suggesting a sustainable, service-driven business model. Roowin's ability to scale its offerings and attract larger clients will be key to its growth trajectory, particularly as demand for outsourced early-stage chemistry services continues to rise.

Upcoming Catalysts (preview)

• 2026-2027Expansion of cGMP manufacturing capacity at Riom facility70% success
• 2026-2028Strategic partnership with a mid-to-large pharma company for API development40% success
• 2027-2028Achievement of FDA or EMA compliance certification for clinical supply50% success